204 related articles for article (PubMed ID: 29567034)
1. Squalene containing solid lipid nanoparticles, a promising adjuvant system for yeast vaccines.
Stelzner JJ; Behrens M; Behrens SE; Mäder K
Vaccine; 2018 Apr; 36(17):2314-2320. PubMed ID: 29567034
[TBL] [Abstract][Full Text] [Related]
2. Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
Skrastina D; Petrovskis I; Lieknina I; Bogans J; Renhofa R; Ose V; Dishlers A; Dekhtyar Y; Pumpens P
PLoS One; 2014; 9(12):e114006. PubMed ID: 25436773
[TBL] [Abstract][Full Text] [Related]
3. The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination.
Vono M; Taccone M; Caccin P; Gallotta M; Donvito G; Falzoni S; Palmieri E; Pallaoro M; Rappuoli R; Di Virgilio F; De Gregorio E; Montecucco C; Seubert A
Proc Natl Acad Sci U S A; 2013 Dec; 110(52):21095-100. PubMed ID: 24324152
[TBL] [Abstract][Full Text] [Related]
4. An alternative renewable source of squalene for use in emulsion adjuvants.
Brito LA; Chan M; Baudner B; Gallorini S; Santos G; O'Hagan DT; Singh M
Vaccine; 2011 Aug; 29(37):6262-8. PubMed ID: 21723355
[TBL] [Abstract][Full Text] [Related]
5. Vaccine adjuvant activity of emulsified oils from species of the Pinaceae family.
Fox CB; Van Hoeven N; Granger B; Lin S; Guderian JA; Hartwig A; Marlenee N; Bowen RA; Soultanov V; Carter D
Phytomedicine; 2019 Nov; 64():152927. PubMed ID: 31465981
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of Freeze-Drying Oil-in-Water Emulsion Adjuvants and Subunit Proteins to Enable Single-Vial Vaccine Drug Products.
Iyer V; Cayatte C; Marshall JD; Sun J; Schneider-Ohrum K; Maynard SK; Rajani GM; Bennett AS; Remmele RL; Bishop SM; McCarthy MP; Muralidhara BK
J Pharm Sci; 2017 Jun; 106(6):1490-1498. PubMed ID: 28259764
[TBL] [Abstract][Full Text] [Related]
7. Advancing Freund's and AddaVax Adjuvant Regimens Using CpG Oligodeoxynucleotides.
Hawksworth D
Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):195-199. PubMed ID: 30281392
[TBL] [Abstract][Full Text] [Related]
8. A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: development, characterization, stability and in vivo evaluation.
Deng J; Cai W; Jin F
Int J Pharm; 2014 Jul; 468(1-2):187-95. PubMed ID: 24704309
[TBL] [Abstract][Full Text] [Related]
9. Chitosan modified squalene nanostructured lipid carriers as a promising adjuvant for freeze-dried ovalbumin vaccine.
Gao X; Gong J; Cai Y; Wang J; Wen J; Peng L; Ji H; Jiang S; Guo D
Int J Biol Macromol; 2021 Oct; 188():855-862. PubMed ID: 34411614
[TBL] [Abstract][Full Text] [Related]
10. A clinically applicable adjuvant for an atherosclerosis vaccine in mice.
Kobiyama K; Vassallo M; Mitzi J; Winkels H; Pei H; Kimura T; Miller J; Wolf D; Ley K
Eur J Immunol; 2018 Sep; 48(9):1580-1587. PubMed ID: 29932463
[TBL] [Abstract][Full Text] [Related]
11. Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants.
Iyer V; Cayatte C; Guzman B; Schneider-Ohrum K; Matuszak R; Snell A; Rajani GM; McCarthy MP; Muralidhara B
Hum Vaccin Immunother; 2015; 11(7):1853-64. PubMed ID: 26090563
[TBL] [Abstract][Full Text] [Related]
12. Adjuvants for Clostridium tetani and Clostridium diphtheriae vaccines updating.
Alshanqiti FM; Al-Masaudi SB; Al-Hejin AM; Redwan EM
Hum Antibodies; 2017; 25(1-2):23-29. PubMed ID: 27858706
[TBL] [Abstract][Full Text] [Related]
13. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect.
Calabro S; Tritto E; Pezzotti A; Taccone M; Muzzi A; Bertholet S; De Gregorio E; O'Hagan DT; Baudner B; Seubert A
Vaccine; 2013 Jul; 31(33):3363-9. PubMed ID: 23684834
[TBL] [Abstract][Full Text] [Related]
14. Sub-unit vaccine against S. aureus-mediated infections: set-up of nano-sized polymeric adjuvant.
Colonna C; Dorati R; Conti B; Caliceti P; Genta I
Int J Pharm; 2013 Aug; 452(1-2):390-401. PubMed ID: 23707885
[TBL] [Abstract][Full Text] [Related]
15. Molecular Design of Squalene/Squalane Countertypes via the Controlled Oligomerization of Isoprene and Evaluation of Vaccine Adjuvant Applications.
Adlington K; El Harfi J; Li J; Carmichael K; Guderian JA; Fox CB; Irvine DJ
Biomacromolecules; 2016 Jan; 17(1):165-72. PubMed ID: 26652915
[TBL] [Abstract][Full Text] [Related]
16. Unsaturated Squalene Content in Emulsion Vaccine Adjuvants Plays a Crucial Role in ROS-Mediated Antigen Uptake and Cellular Immunity.
Huang CH; Huang CY; Huang MH
Mol Pharm; 2018 Feb; 15(2):420-429. PubMed ID: 29237267
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.
Fox CB; Baldwin SL; Duthie MS; Reed SG; Vedvick TS
AAPS PharmSciTech; 2012 Jun; 13(2):498-506. PubMed ID: 22415641
[TBL] [Abstract][Full Text] [Related]
18. The ABC of clinical and experimental adjuvants--a brief overview.
Brunner R; Jensen-Jarolim E; Pali-Schöll I
Immunol Lett; 2010 Jan; 128(1):29-35. PubMed ID: 19895847
[TBL] [Abstract][Full Text] [Related]
19. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method.
Klucker MF; Dalençon F; Probeck P; Haensler J
J Pharm Sci; 2012 Dec; 101(12):4490-500. PubMed ID: 22941944
[TBL] [Abstract][Full Text] [Related]
20. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines.
Ott G; Barchfeld GL; Chernoff D; Radhakrishnan R; van Hoogevest P; Van Nest G
Pharm Biotechnol; 1995; 6():277-96. PubMed ID: 7551221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
